Menu Search
Equities

Theraclion SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
941:MUN

Theraclion SA

Actions
  • Price (EUR)0.67
  • Today's Change0.00 / 0.00%
  • Shares traded713.00
  • 1 Year change+176.86%
  • Beta-0.3997
Data delayed at least 15 minutes, as of Feb 06 2026 07:38 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Theraclion SA is a France-based company, which develops High Intensity Focused Ultrasound (HiFu) machines. The Company is a a spin-off of Inserm and EDAPTechomed. The main activity of the Company is developping, manufacturing and marketing echotherapy medical equipments associating therapy by focused ultrasound and monitoring by ultrasound. The Company provides Echopulse, a device for the non-invasive and outpatient treatment of the fibroadenoma of the breast and thyroid nodules.

  • Revenue in EUR (TTM)1.90m
  • Net income in EUR-5.25m
  • Incorporated2004
  • Employees33.00
  • Location
    Theraclion SA244, avenue Pierre BrossoletteMALAKOFF 92240FranceFRA
  • Phone+33 155489070
  • Fax+33 155489078
  • Websitehttps://www.theraclion.fr/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.